Satsuma Pharmaceuticals STSA

$ 1.1 -0.9%

Quarterly report 2023-Q1
added 05-11-2023

Satsuma Pharmaceuticals Income Statement 2011-2024 | STSA

Annual Income Statement Satsuma Pharmaceuticals

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Market Cap	27.2 M	121 M	101 M	150 M	-	-	-	-	-	-	-	-
Shares	32 M	29.2 M	17.4 M	5.86 M	-	-	-	-	-	-	-	-
Historical Prices	0.85	4.16	5.68	28.5	-	-	-	-	-	-	-	-
Net Income	-70.1 M	-51.2 M	-47.6 M	-28.2 M	-7.35 M	-5.17 M	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-70.9 M	-51.2 M	-48.3 M	-28.9 M	-7.52 M	-4.95 M	-	-	-	-	-	-
Interest Expense	13 K	163 K	350 K	482 K	90 K	15 K	-	-	-	-	-	-
EBITDA	-70.4 M	-50.8 M	-47 M	-28.7 M	-7.2 M	-5.15 M	-	-	-	-	-	-
Operating Expenses	70.9 M	51.2 M	48.3 M	28.9 M	-	-	-	-	-	-	-	-
General and Administrative Expenses	15.1 M	13.5 M	12.1 M	4.68 M	1.08 M	754 K	-	-	-	-	-	-

All numbers in USD currency

Quarterly Income Statement Satsuma Pharmaceuticals

	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	33.2 M	33.2 M	31.9 M	31.6 M	31.5 M	31.5 M	31.5 M	31.5 M	22 M	17.4 M	17.4 M	17.4 M	17.4 M	17.4 M	3.66 M	1.15 M	1.12 M	1.08 M	1.07 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-10.3 M	-	-15.1 M	-16.3 M	-15.5 M	-	-13.3 M	-11.8 M	-10.5 M	-12.5 M	-12 M	-11.3 M	-11.8 M	-10.8 M	-8.26 M	-6.29 M	-2.82 M	-2.34 M	-1.59 M	-2.2 M	-1.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Income	-10.8 M	-	-15.4 M	-16.4 M	-15.5 M	-	-13.3 M	-11.8 M	-10.4 M	-12.5 M	-12.2 M	-11.5 M	-12.2 M	-11.3 M	-8.47 M	-6.42 M	-2.71 M	-2.28 M	-1.6 M	-2.22 M	-1.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expense	-	-	13 K	2 K	11 K	-	35 K	47 K	57 K	-	82 K	94 K	104 K	-	121 K	122 K	122 K	-	2 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBITDA	-	-	-15.3 M	-16.3 M	-15.5 M	-	-13.2 M	-11.7 M	-10.4 M	-12.5 M	-12 M	-11.4 M	-12.1 M	-11.3 M	-8.37 M	-6.36 M	-2.68 M	-2.28 M	-1.57 M	-2.22 M	-1.41 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	10.8 M	-	15.4 M	16.4 M	15.5 M	-	13.3 M	11.8 M	10.4 M	-	12.2 M	11.5 M	12.2 M	-	8.47 M	6.42 M	2.71 M	-	1.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and Administrative Expenses	3.31 M	-	4.07 M	3.9 M	3.99 M	-	3.16 M	3.38 M	3.29 M	-	3.42 M	2.67 M	2.52 M	-	1.03 M	967 K	564 K	-	220 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency